Salvador Cabrera Figueroa

Summary

Affiliation: Universidad Austral de Chile
Country: Chile

Publications

  1. ncbi The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 32:579-85. 2010
  2. ncbi Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Clin Drug Investig 30:405-11. 2010
  3. ncbi Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients
    Elena López Aspiroz
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 33:573-82. 2011

Collaborators

  • Elena López Aspiroz
  • María José García Sánchez
  • Esteban Ribera Pascuet
  • Dolores Santos Buelga
  • Alfonso Domínguez-Gil Hurlé
  • Rosa María López Galera

Detail Information

Publications3

  1. ncbi The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 32:579-85. 2010
    ..As genotype screens become cheaper, and in combination with TDM, adjusting dosages in the light of genetic polymorphisms will become a reality...
  2. ncbi Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV
    Salvador Cabrera Figueroa
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Clin Drug Investig 30:405-11. 2010
    ..This also resulted in a reduction in ADEs. At present, the patient's CD4+ levels remain stable, his viral load continues to be undetectable and the mean efavirenz C(min,ss) is within the therapeutic range (2.7 mg/L)...
  3. ncbi Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients
    Elena López Aspiroz
    Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain
    Ther Drug Monit 33:573-82. 2011
    ..Therefore, it is important to increase our knowledge about factors that determine interpatient variability in LPV pharmacokinetics (PK)...